Allergan Receives FDA Approval for Juvederm with Lidocaine
Posted by Cosmetic Surgery Review on February 24, 2010
The hyaluronic acid filler is administered to reduce the appearance of fine lines and wrinkles, and is especially effective for treating nasolabial folds around the nose and mouth area. Now, the injectable has been formulated with lidocaine to ward off pain and increase the patient’s level of comfort.
The U.S. Food and Drug Administration has approved the dermal filler with lidocaine for use n the consumer market, making Juvederm the first and only dermal filler to have received FDA approval for up to one year from initial treatment.
According to Robert Grant, Corporate Vice President of Allergan and President of Allergan Medical, “We lead innovation in the dermal filler category with the first and only smooth-consistency gel hyaluronic acid dermal filler approved by the FDA to last up to a year. Now we have added lidocaine to Juvederm to provide the same smooth, long-lasting result, but with additional comfort for patients.”
Lidocaine helps to numb the treatment area within seconds of being injected into the skin, which means the administering physician or medical professional does not need to apply topical numbing agents to the area. Juvederm can be administered in several areas of the face at once, and produces instant results that can last for several months.
Before Juvederm was formulated with Lidocaine, it could take up to 30 minutes for the topical anesthetic to begin working, and many patients still tolerated a certain level of pain during and after the treatment. Lidocaine helps to minimize the effects of the acid going into the dermis, and also reduces pain from the injection’s needle.
Juvederm with lidocaine is now available nationwide, and is available only by a prescription by a certified medical practitioner.